Nidlegy™ is partnered with Sun Pharma for the treatment of Skin Cancers in Europe, New Zealand and Australia. Both companies jointly made the following announcements: - 23 October 2023 - Phase III PIVOTAL trial met the primary endpoint
- 31 May 2024 – Primary results of PIVOTAL presented at ASCO
- 04 June 2024 – MAA submission to EMA
The data of the Phase III Nidlegy™ trial are expected to be published in a peer-reviewed scientific journal in 2024.